Publication:
Evaluation of the Chagas VirClia® and Chagas TESA VirClia® for the Diagnosis of Trypanosoma cruzi Infection

Simple item page
dc.contributor.authorGarcía-Bermejo, Isabel
dc.contributor.authorMolina Arana, David
dc.contributor.authorZaragoza Vargas, Gloria
dc.contributor.authorCarrasco Fernández, Blanca
dc.contributor.authorGarcia, Emilia
dc.contributor.authorNieto Martinez, Francisco Javier
dc.contributor.authorFlores-Chavez, Maria
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderFundación Mundo Sanoes_ES
dc.date.accessioned2023-07-17T09:35:56Z
dc.date.available2023-07-17T09:35:56Z
dc.date.issued2023
dc.description.abstractChagas disease (CD), caused by the protozoan Trypanosoma cruzi, is an important problem of public health even in regions where it is not endemic. Spain ranks second worldwide in terms of imported cases of T. cruzi infection in the chronic phase. The diagnosis in this stage is made via the detection of antibodies against T. cruzi. Therefore, we aimed to evaluate the sensitivity and specificity of two fully automated chemiluminescence immunoassays, Chagas VirClia® (CHR), which uses a mixture of recombinant antigens, and Chagas TESA VirClia® (TESA), the first chemiluminescence assay based on excretion-secretion antigens of trypomastigotes, both designed in monotest format. A retrospective case-control study was performed using 105 well-characterized samples: 49 from patients with CD, 22 from uninfected individuals, and 32 from patients with other pathologies. Sensitivity was 98% for CHR and 92% for TESA. In contrast, the specificity in both was 100%. Cross-reactivity was observed in leishmaniasis (2/10). CHR meets the criteria to become a tool for serological screening, while TESA has the potential for confirmation and cross-reaction discrimination. The monotest format allows its application in laboratories with a small number of samples. The high specificity of both assays is useful in areas where leishmaniasis is endemic.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThis research was funded by Surveillance Program of Chagas disease in Spain of CNM, Instituto de Salud Carlos III (ISCIII), Madrid, Spain, and Mundo Sano Foundation-Spain.es_ES
dc.format.number1es_ES
dc.format.page50es_ES
dc.format.volume12es_ES
dc.identifier.citationPathogens. 2023;12(1):50.es_ES
dc.identifier.doi10.3390/pathogens12010050es_ES
dc.identifier.issn2076-0817es_ES
dc.identifier.journalPathogens (Basel, Switzerland)es_ES
dc.identifier.pubmedID36678398es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16260
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/pathogens12010050es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectChagas diseasees_ES
dc.subjectTrypanosoma cruzi infectiones_ES
dc.subjectSerological diagnosises_ES
dc.subjectSensitivityes_ES
dc.subjectSpecificityes_ES
dc.subjectChemiluminescence immunoassayes_ES
dc.subjectRecombinant antigenses_ES
dc.subjectTESAes_ES
dc.titleEvaluation of the Chagas VirClia® and Chagas TESA VirClia® for the Diagnosis of Trypanosoma cruzi Infectiones_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EvaluationChagasVirCliaChagasTESAVirClia_2023.pdf
Size:
478.08 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Centro Nacional de Microbiología (CNM)